Related Experiment Video
Updated: May 8, 2026
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Evaluation of the oral direct factor Xa inhibitor - betrixaban
Michael Palladino1, Geno Merli, Lynda Thomson
1Thomas Jefferson University Hospital, Department of Pharmacy - Vascular Medicine , 111 South 10th St, Philadelphia, PA 19107 , USA +1609 706 5271 ; Michael.palladino@jeffersonhospital.org.
Introduction:
For over 60 years vitamin K antagonists have been the mainstay of oral therapy for treatment and prevention of venous and arterial thromboembolic disease. The emergence of two new classes of orally administered anticoagulants, direct thrombin and factor Xa inhibitors have drastically changed the landscape in the management of these disease states. Betrixaban , an orally administered direct factor Xa inhibitor, is entering a Phase III trial and undergoing investigation for similar indications as apixaban, dabigatran and rivaroxaban.
Areas Covered:
The chemical development of betrixaban, pharmacokinetic differences between betrixaban and currently available novel anticoagulants and future considerations for clinical use.
Expert Opinion:
Betrixaban, the fifth novel oral anticoagulant in line for the Food and Drug Administration (FDA) approval, possesses some unique pharmacokinetic characteristics in comparison with the currently available novel anticoagulants, including limited renal excretion, minimal metabolism through the cytochrome p450 system and a long half-life. This pharmacokinetic profile may allow greater flexibility for use in patients with poor renal function, offer the convenience of once daily dosing, and exhibit less drug interactions. Betrixaban is currently being evaluated for prophylaxis against venous thromboembolic disease (VTED) and the prevention of stroke and systemic embolism associated with nonvalvular atrial fibrillation, its role in the management of acute VTED and acute coronary syndromes is yet to be defined based on clinical data and evaluation. Of interest, a factor Xa decoy, PRT4445, is currently under evaluation in conjunction with betrixaban, and may be a universal reversal agent for all anticoagulants with anti-Xa activity. Currently, there are no specific reversal agents for the novel anticoagulants. The availability of an effective reversal agent would be very attractive for the management of associated bleeding, bleeding due to trauma, or the need for emergent surgery.
Insights
Betrixaban, a novel oral anticoagulant, offers unique pharmacokinetic advantages like limited kidney excretion and minimal drug interactions. This factor Xa inhibitor may provide dosing flexibility for patients with renal impairment.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Development
Background:
- Vitamin K antagonists have long been standard for thromboembolic disease.
- Novel oral anticoagulants, including direct thrombin and factor Xa inhibitors, have transformed treatment.
- Betrixaban, a direct factor Xa inhibitor, is under investigation for similar uses as apixaban, dabigatran, and rivaroxaban.
Purpose of the Study:
- To review the chemical development of betrixaban.
- To compare pharmacokinetic profiles of betrixaban with other novel anticoagulants.
- To discuss future clinical applications of betrixaban.
Main Methods:
- Review of chemical development processes for betrixaban.
- Comparative pharmacokinetic analysis of betrixaban versus existing novel anticoagulants.
- Evaluation of potential clinical use scenarios and future considerations.
Main Results:
- Betrixaban exhibits limited renal excretion and minimal cytochrome P450 metabolism.
- It possesses a long half-life, suggesting potential for once-daily dosing.
- Its unique profile may offer improved flexibility for patients with renal dysfunction and fewer drug interactions.
Conclusions:
- Betrixaban, nearing FDA approval, has distinct pharmacokinetics compared to current novel anticoagulants.
- Its profile may enhance usability in patients with renal impairment and reduce drug interactions.
- A reversal agent, PRT4445, is being evaluated for factor Xa inhibitors, addressing a critical unmet need for managing bleeding events.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Therapeutic Drug Monitoring: Affecting Factors
01:25Antihypertensive Drugs: Direct Renin Inhibitors